Rates of obesity in older adults roughly doubled between 1988-94 and 2015-18, according to a report by the Population Reference Bureau
Retatrutide (development code LY3437943 ) is an investigational synthetic peptide developed by Eli Lilly and Company that has rapidly become one of the most closely watched molecules in metabolic research
Remove the plastic protective caps from both the Retatrutide vial and the Bacteriostatic Water vial
Greater Weight Loss Clinical Trial Data: In the Phase 2 TRIUMPH-1 study , retatrutide achieved unprecedented levels of weight loss : Up to 24.2% average total body weight loss at 48 weeks Over 26% weight loss at the highest dose (12 mg weekly) In comparison: Tirzepatides weight loss peaked at about 22.5% in SURMOUNT-1 at 72 weeks This suggests faster, more significant fat loss in less time with retatrutide
199 Activated Akt promotes the expression and translocation of GLUT4 (Glucose Transporter Type 4) to the cell membrane, increasing cellular glucose uptake
Side effects may be related to dose, titration speed, meal patterns, hydration, constipation, reflux, or other medications
